Request Demo
Last update 20 Mar 2025
SAN-300
Last update 20 Mar 2025
Overview
Basic Info
Drug Type Monoclonal antibody |
Synonyms Anti-VLA-1 antibody, Anti-VLA-1 mAb + [1] |
Target |
Action antagonists |
Mechanism α1β1 antagonists(Integrin alpha1/beta1 antagonists) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
2
Clinical Trials associated with SAN-300NCT02047604
A Randomized, Double-blind, Placebo-Controlled, Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Escalating Doses of SAN-300 in Patients With Active Rheumatoid Arthritis With Inadequate Response to Disease-Modifying Anti-rheumatic Drug(s).
ACTRN12611000123943
A phase 1 study of healthy subjects and patients with rheumatoid arthritis receiving single doses of SAN-300 or placebo to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SAN-300
100 Clinical Results associated with SAN-300
Login to view more data
100 Translational Medicine associated with SAN-300
Login to view more data
100 Patents (Medical) associated with SAN-300
Login to view more data
1
Literatures (Medical) associated with SAN-30001 Jun 2007Archives of Ophthalmology
Very Late Antigen 1 Blockade Markedly Promotes Survival of Corneal Allografts
Article
Author: de Fougerolles, Antonin R. ; Barabino, Stefano ; Gardner, Humphrey ; Chen, Lu ; Dana, M. Reza ; Huq, Syed
100 Deals associated with SAN-300
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Rheumatoid Arthritis | Phase 2 | - | - |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Phase 2 | 41 | (Cohort A - SAN-300 0.5 mg/kg QW) | zyoudargui(wjukfmnakq) = dlndumjqbp waggnlweri (zjlajqsoew, isqieojxws - memsjztepq) View more | - | 21 Jun 2021 | ||
(Cohort B - SAN-300 1.0 mg/kg QW) | zyoudargui(wjukfmnakq) = qcrbwswcfj waggnlweri (zjlajqsoew, lieqflkara - kksqzlpolq) View more |
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free